Cargando…

Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach

(1) Background: Prostate-specific membrane antigen (PSMA) has been extensively studied in the last decade. It became a promising biological target in the diagnosis and therapy of PSMA-expressing cancer diseases. Although there are several radiolabeled PSMA inhibitors available, the search for new co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lahnif, Hanane, Grus, Tilmann, Pektor, Stefanie, Greifenstein, Lukas, Schreckenberger, Mathias, Rösch, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8588462/ https://www.ncbi.nlm.nih.gov/pubmed/34770742 http://dx.doi.org/10.3390/molecules26216332

Ejemplares similares

Old Drug, New Delivery Strategy: MMAE Repackaged
por: Lahnif, Hanane, et al.
Publicado: (2023)

Instant kit preparation of (68)Ga-radiopharmaceuticals via the hybrid chelator DATA: clinical translation of [(68)Ga]Ga-DATA-TOC
por: Sinnes, Jean-Philippe, et al.
Publicado: (2019)

PSA and PSA Kinetics Thresholds for the Presence of (68)Ga-PSMA-11 PET/CT-Detectable Lesions in Patients with Biochemical Recurrent Prostate Cancer
por: Hoffmann, Manuela Andrea, et al.
Publicado: (2020)

Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals()
por: Cai, Zhengxin, et al.
Publicado: (2013)

Modern Developments in Bifunctional Chelator Design for Gallium Radiopharmaceuticals
por: Davey, Patrick R. W. J., et al.
Publicado: (2022)

First‐Generation Bispidine Chelators for (213)Bi(III) Radiopharmaceutical Applications
por: Bruchertseifer, Frank, et al.
Publicado: (2020)

Click-to-Chelate: Development of Technetium and Rhenium-Tricarbonyl Labeled Radiopharmaceuticals
por: Kluba, Christiane A., et al.
Publicado: (2013)

AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications
por: Fersing, Cyril, et al.
Publicado: (2022)

PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials
por: Ramnaraign, Brian, et al.
Publicado: (2023)

PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives
por: El Fakiri, Mohamed, et al.
Publicado: (2021)

Hydroxypyridinone Chelators: From Iron Scavenging to Radiopharmaceuticals for PET Imaging with Gallium-68
por: Cusnir, Ruslan, et al.
Publicado: (2017)

The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker
por: Holik, Holis Abdul, et al.
Publicado: (2022)

Dual-Time Point [(68)Ga]Ga-PSMA-11 PET/CT Hybrid Imaging for Staging and Restaging of Prostate Cancer
por: Hoffmann, Manuela A., et al.
Publicado: (2020)

Refined Chelator Spacer Moieties Ameliorate the Pharmacokinetics of PSMA-617
por: dos Santos, José Carlos, et al.
Publicado: (2022)

Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC
por: Rosar, Florian, et al.
Publicado: (2022)

Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA(5m) chelators
por: Moon, Euy Sung, et al.
Publicado: (2020)

Comparison of [(18)F]PSMA-1007 with [(68)Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Diagnostic performance of (68)Gallium-PSMA-11 PET/CT to detect significant prostate cancer and comparison with (18)FEC PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2017)

In vivo imaging of the immune response upon systemic RNA cancer vaccination by FDG-PET
por: Pektor, Stefanie, et al.
Publicado: (2018)

The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review
por: Rizzo, Alessio, et al.
Publicado: (2023)

Value of Combined PET Imaging with [(18)F]FDG and [(68)Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [(177)Lu]Lu-PSMA-617 RLT
por: Khreish, Fadi, et al.
Publicado: (2021)

Alternative Chelator for (89)Zr Radiopharmaceuticals: Radiolabeling and Evaluation of 3,4,3-(LI-1,2-HOPO)
por: Deri, Melissa A., et al.
Publicado: (2014)

Early molecular imaging response assessment based on determination of total viable tumor burden in [(68)Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [(177)Lu]Lu-PSMA-617 radioligand therapy
por: Rosar, Florian, et al.
Publicado: (2021)

[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021)

Labeling of DOTA-conjugated HPMA-based polymers with trivalent metallic radionuclides for molecular imaging
por: Eppard, Elisabeth, et al.
Publicado: (2018)

3p-C-NETA: A versatile and effective chelator for development of Al(18)F-labeled and therapeutic radiopharmaceuticals
por: Ahenkorah, Stephen, et al.
Publicado: (2022)

MIB Guides: Preclinical radiopharmaceutical dosimetry
por: Carter, Lukas M., et al.
Publicado: (2023)

Toxicity Assessment of [(177)Lu]Lu−iFAP/iPSMA Nanoparticles Prepared under GMP-Compliant Radiopharmaceutical Processes
por: Hernández-Jiménez, Tania, et al.
Publicado: (2022)

Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples
por: Kolenc Peitl, Petra, et al.
Publicado: (2019)

Separation of (44)Sc from (44)Ti in the Context of A Generator System for Radiopharmaceutical Purposes with the Example of [(44)Sc]Sc-PSMA-617 and [(44)Sc]Sc-PSMA-I&T Synthesis
por: Larenkov, Anton A., et al.
Publicado: (2021)

One-step, kit-based radiopharmaceuticals for molecular SPECT imaging: a versatile diphosphine chelator for (99m)Tc radiolabelling of peptides
por: Hungnes, Ingebjørg N., et al.
Publicado: (2021)

Radiopharmaceuticals for therapy
por: Knapp, F F (Russ), et al.
Publicado: (2016)

PET Radiopharmaceuticals
por: Shahhosseini, Soraya
Publicado: (2011)

Pharmacovigilance in radiopharmaceuticals
por: Kumar, Rishi, et al.
Publicado: (2016)

From Automated Synthesis to In Vivo Application in Multiple Types of Cancer—Clinical Results with [(68)Ga]Ga-DATA(5m).SA.FAPi
por: Greifenstein, Lukas, et al.
Publicado: (2022)

Comparison Study of Two Differently Clicked (18)F-Folates—Lipophilicity Plays a Key Role
por: Kettenbach, Kathrin, et al.
Publicado: (2018)

Novel Preclinical and Radiopharmaceutical Aspects of [(68)Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer
por: Eder, Matthias, et al.
Publicado: (2014)

Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis
por: Rizzo, Alessio, et al.
Publicado: (2022)

Preclinical Evaluation of a Companion Diagnostic Radiopharmaceutical, [(18)F]PSMA-1007, in a Subcutaneous Prostate Cancer Xenograft Mouse Model
por: Kim, Su Bin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ushj3na30a1nf7d4cv6kkvqiab